dijous, 30 de juliol del 2015

MassDevice.com +3 | The top 3 medtech stories for July30, 2015

Plus 3

Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.

 

3. Abbott drops $250m on Tendyne, backs Cephea in mitral valve play

MassDevice.com news

CEO Miles White proved today that he wasn’t just blowing smoke last week when he said that Abbott has powder to burn and is ready to use it.

Abbott today revealed a pair of investments aimed at building out its presence in the mitral valve replacement market, saying it put another $225 million on top of the stake it already owns in Tendyne Holdings and announcing an unspecified strategic investment in Cephea Valve Technologies. Read more


2. Zimmer Biomet surprises with Q2 earnings beat

MassDevice.com news

Zimmer Biomet surprised analysts with its 2nd-quarter earnings in the 1st quarterly report since closing the $14 billion merger with Biomet last month.

Despite a swing to red ink, Warsaw, Ind.-based Zimmer Biomet posted adjusted earnings per share of $1.59 for the 3 months ended June 30, 4¢ ahead of expectations on Wall Street. That excludes 1-time items, including $390.6 million in merger-related expenses. Read more


1. GE Healthcare to drop $1B on healthcare provider education

MassDevice.com news

GE Healthcare said it is investing $1 billion in healthcare provider education and training over the next 5 years.

GE Healthcare said the enhanced training will reach more than 2 million healthcare professionals by 2020 and help more than 300 million patients. The program will deliver localized offerings and include technology-enabled training solutions. Read more

The post MassDevice.com +3 | The top 3 medtech stories for July30, 2015 appeared first on MassDevice.



from MassDevice http://ift.tt/1SPy0YC

Cap comentari:

Publica un comentari a l'entrada